Sutro Biopharma

$4.45 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Sutro Biopharma

Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The Company is focused on using its integrated cell-free protein synthesis platform, XpressCF, to create a variety of protein therapeutics for cancer and autoimmune disorders. It focuses to design therapeutics using potent modalities, including cytokine-based immuno-oncology (I/O) therapeutics, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed primarily against clinically validated targets. Its product candidate includes STRO-001 and STRO-002. STRO-001 is an ADC directed against the cancer target CD74, for patients with multiple myeloma and non-Hodgkin lymphoma (NHL). STRO-002 is an ADC directed against folate receptor-alpha (FolRa), for patients with ovarian and endometrial cancers. STRO-001 and STRO-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its XpressCF Platform.

Stock Analysis

last close $4.45
1-mo return -36%
3-mo return -49.5%
avg daily vol. 565.3T
52-week high 23.7
52-week low 4.36
market cap. $219M
forward pe -
annual div. -
roe -43.3%
ltg forecast -
dividend yield -
annual rev. $53M
inst own. 91.8%

Subscribe now for daily local and international financial news